Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 78

1.

Influence of Glass Forming Ability on the Physical Stability of Supersaturated Amorphous Solid Dispersions.

Blaabjerg LI, Bulduk B, Lindenberg E, Löbmann K, Rades T, Grohganz H.

J Pharm Sci. 2019 Mar 13. pii: S0022-3549(19)30151-0. doi: 10.1016/j.xphs.2019.02.028. [Epub ahead of print]

PMID:
30878513
2.

Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy.

Bohr A, Nascimento TL, Harmankaya N, Weisser JJ, Wang Y, Grohganz H, Rades T, Löbmann K.

Molecules. 2019 Jan 11;24(2). pii: E266. doi: 10.3390/molecules24020266.

3.

In situ co-amorphisation in coated tablets - The combination of carvedilol with aspartic acid during immersion in an acidic medium.

Petry I, Löbmann K, Grohganz H, Rades T, Leopold CS.

Int J Pharm. 2019 Mar 10;558:357-366. doi: 10.1016/j.ijpharm.2018.12.091. Epub 2019 Jan 12.

PMID:
30641182
4.

Process Optimization and Upscaling of Spray-Dried Drug-Amino acid Co-Amorphous Formulations.

Kasten G, Duarte Í, Paisana M, Löbmann K, Rades T, Grohganz H.

Pharmaceutics. 2019 Jan 9;11(1). pii: E24. doi: 10.3390/pharmaceutics11010024.

5.

Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.

Wu W, Wang Y, Löbmann K, Grohganz H, Rades T.

Mol Pharm. 2019 Mar 4;16(3):1294-1304. doi: 10.1021/acs.molpharmaceut.8b01229. Epub 2019 Jan 25.

PMID:
30624075
6.

Co-former selection for co-amorphous drug-amino acid formulations.

Kasten G, Löbmann K, Grohganz H, Rades T.

Int J Pharm. 2019 Feb 25;557:366-373. doi: 10.1016/j.ijpharm.2018.12.036. Epub 2018 Dec 19.

PMID:
30578980
7.

Whey proteins as stabilizers in amorphous solid dispersions.

Mishra J, Bohr A, Rades T, Grohganz H, Löbmann K.

Eur J Pharm Sci. 2019 Feb 1;128:144-151. doi: 10.1016/j.ejps.2018.12.002. Epub 2018 Dec 4.

PMID:
30528387
8.

Dipeptides as co-formers in co-amorphous systems.

Wu W, Löbmann K, Schnitzkewitz J, Knuhtsen A, Pedersen DS, Rades T, Grohganz H.

Eur J Pharm Biopharm. 2019 Jan;134:68-76. doi: 10.1016/j.ejpb.2018.11.016. Epub 2018 Nov 20.

PMID:
30468836
9.

In situ co-amorphisation of arginine with indomethacin or furosemide during immersion in an acidic medium - A proof of concept study.

Petry I, Löbmann K, Grohganz H, Rades T, Leopold CS.

Eur J Pharm Biopharm. 2018 Dec;133:151-160. doi: 10.1016/j.ejpb.2018.10.011. Epub 2018 Oct 16.

PMID:
30339888
10.

Influence of preparation technique on co-amorphization of carvedilol with acidic amino acids.

Mishra J, Löbmann K, Grohganz H, Rades T.

Int J Pharm. 2018 Dec 1;552(1-2):407-413. doi: 10.1016/j.ijpharm.2018.09.070. Epub 2018 Sep 29.

PMID:
30278256
11.

In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.

Kasten G, Lobo L, Dengale S, Grohganz H, Rades T, Löbmann K.

Eur J Pharm Biopharm. 2018 Nov;132:192-199. doi: 10.1016/j.ejpb.2018.09.024. Epub 2018 Sep 25.

PMID:
30266670
12.

The Influence of Polymers on the Supersaturation Potential of Poor and Good Glass Formers.

Blaabjerg LI, Grohganz H, Lindenberg E, Löbmann K, Müllertz A, Rades T.

Pharmaceutics. 2018 Sep 21;10(4). pii: E164. doi: 10.3390/pharmaceutics10040164.

13.

Aspartame as a co-former in co-amorphous systems.

Wu W, Löbmann K, Schnitzkewitz J, Knuhtsen A, Pedersen DS, Grohganz H, Rades T.

Int J Pharm. 2018 Oct 5;549(1-2):380-387. doi: 10.1016/j.ijpharm.2018.07.063. Epub 2018 Jul 31.

PMID:
30075253
14.

Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems.

Wu W, Ueda H, Löbmann K, Rades T, Grohganz H.

Eur J Pharm Biopharm. 2018 Oct;131:25-32. doi: 10.1016/j.ejpb.2018.07.016. Epub 2018 Jul 21.

PMID:
30040997
15.

The Role of Glass Transition Temperatures in Coamorphous Drug-Amino Acid Formulations.

Kissi EO, Kasten G, Löbmann K, Rades T, Grohganz H.

Mol Pharm. 2018 Sep 4;15(9):4247-4256. doi: 10.1021/acs.molpharmaceut.8b00650. Epub 2018 Jul 30.

PMID:
30020794
16.

Using dextran of different molecular weights to achieve faster freeze-drying and improved storage stability of lactate dehydrogenase.

Larsen BS, Skytte J, Svagan AJ, Meng-Lund H, Grohganz H, Löbmann K.

Pharm Dev Technol. 2019 Mar;24(3):323-328. doi: 10.1080/10837450.2018.1479866. Epub 2018 Jun 20.

PMID:
29781745
17.

Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions.

Petry I, Löbmann K, Grohganz H, Rades T, Leopold CS.

Int J Pharm. 2018 Jun 10;544(1):172-180. doi: 10.1016/j.ijpharm.2018.04.026. Epub 2018 Apr 15.

PMID:
29669257
18.

The use of molecular descriptors in the development of co-amorphous formulations.

Meng-Lund H, Kasten G, Jensen KT, Poso A, Pantsar T, Rades T, Rantanen J, Grohganz H.

Eur J Pharm Sci. 2018 Jul 1;119:31-38. doi: 10.1016/j.ejps.2018.04.014. Epub 2018 Apr 10.

PMID:
29649569
19.

Influence of Solvent Composition on the Performance of Spray-Dried Co-Amorphous Formulations.

Mishra J, Rades T, Löbmann K, Grohganz H.

Pharmaceutics. 2018 Apr 12;10(2). pii: E47. doi: 10.3390/pharmaceutics10020047.

20.

Application of a Salt Coformer in a Co-Amorphous Drug System Dramatically Enhances the Glass Transition Temperature: A Case Study of the Ternary System Carbamazepine, Citric Acid, and l-Arginine.

Ueda H, Wu W, Löbmann K, Grohganz H, Müllertz A, Rades T.

Mol Pharm. 2018 May 7;15(5):2036-2044. doi: 10.1021/acs.molpharmaceut.8b00174. Epub 2018 Apr 13.

PMID:
29630842

Supplemental Content

Loading ...
Support Center